Slide 1: Corporate Presentation
Exhibit 99.2 June 8, 2022 Corporate NASDAQ: BTMD Presentation Confidential Material – Do Not Distribute
Slide 2: Disclaimer: Forward-Looking Statements
Disclaimer Forward-Looking Statements Certain statements in this Presentation may be considered “forward-looking statements” within the meaning of the provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events of Bio
Slide 3: Transforming Healthy Aging
Transforming Healthy Aging • Innovative, personalized hormone therapy delivered by Biote- certified providers with 10-year track record of patient satisfaction • High-growth, profitable, health & wellness company with continued growth potential in the US and globally • Commercial expertise with 5,30
Slide 4: Biote's Numbers Speak for Themselves
Biote’s Numbers Speak for Themselves $46M—$50M $160M—$166M 2022E 2022E EBITDA Revenue • >11x Next-Largest (1) Competitor • $7bn+ Hormone ~20% ~20% ~29% Replacement 2020A – 2022E 2020A – 2022E 2022E (2) Therapy Market Net Revenue CAGR EBITDA CAGR EBITDA Margin • Accelerated Growth • Exceptional Margi
Slide 5: How Hormone Deficiency is Related to Risky and Debilitating Diseases
How Hormone Deficiency is Related to Risky and Debilitating Diseases (1) Hormone Deficiency Symptoms Related Diseases After the age of 40, many of us begin to face these… People with hormone deficiency are at increased risk of… (2)(3) • Low energy• Irritability • Heart disease (4)(5) • Insomnia• Dep
Slide 6: Hormone Therapy is Proven to Provide Symptom Relief
Hormone Therapy is Proven to Provide Symptom Relief (1) (1) (2) Symptom Prevalence Complete Relief Change in Symptom Severity (%) (%) (%) 81.7 Hot flashes / sweats 90.8 ↓ 69 73.5 Insomnia 61.4 ↓ 62 50.0 Dyspareunia 71.6 ↓ 76 83.3 Loss of libido 67.0 ↓ 73 84.2 Irritability 73.3 ↓ 66 79.2 Depression 7
Slide 7: Hormone Deficiency Affects 200M Americans with ~80% Untreated
Hormone Deficiency Affects 200M Americans (1) (2) with ~80% Untreated Addressable Patient Population Female Male Hormone Replacement •Women's estradiol •Men experience a 44% Therapy levels decline 67% from reduction of $7bn+ the mid 40s to the mid testosterone between (8) +7% CAGR (3) (6) 50s ages 3
Slide 8: Biote Offers Providers a Convenient Hormone Therapy Solution in a Clinical Setting
Biote Offers Providers a Convenient Hormone Therapy Solution in a Clinical Setting Medically prescribed by Over-the-Counter Pills providers × Not medically prescribed Personalized dosage with × One-size-fits all approach sustained release × Self-administered × Risk of inconsistent compliance Conveni
Slide 9: Complementary Portfolio of Treatments for Providers
Complementary Portfolio of Treatments for Providers to Address Clear Consumer Health Needs Biote Method Nutraceuticals Revenue % of ‘22 • Dietary supplements that are Revenue ($ in millions) $160-$166 • Proprietary BioTracker Practice supportive to patients undergoing 1% Management Software pellet t
Slide 10: Scaled Market Leader with Differentiated Provider Business Model
Scaled Market Leader with Differentiated Provider Business Model and Unparalleled Operating Experience Customer Support Staff Sales Marketing Training • 80+ national field sales team• In-house full-service marketing and • 1 national training center• 10+ in-house customer support analytics capabiliti
Slide 11: Biote Has An Exceptional Financial Profile
Biote Has An Exceptional Financial Profile Financial Summary Key Stats Revenue ($ in millions) 20% 300k+ ’20-’22 Revenue $160-166 Active Patients of $139 $116 CAGR Providers on Therapy $110 2019A 2020A 2021A 2022E ~29% EBITDA 90% 2022E Margin Clinic Retention Rate EBITDA ($ in millions) $46-50 $36 $
Slide 12: Q1-2022 Performance on Track
Q1-2022 Performance on Track Key Highlights: ✓ Net sales of $37 million in the quarter, an 18% increase YoY ✓ First quarter procedural revenue grew at 21.2% YoY ✓ Adjusted EBITDA of $12 million, a 20% increase YoY ✓ Management reiterates its 2022 guidance: − $160-166 million in revenue and $46-50 mi
Slide 13: Underserved TAM and Affordable Treatment Option
Underserved TAM and Affordable Treatment Option (1) (2) 200M Americans with ~80% Untreated 18-34 18-34 3% 65-74 4% 75+ 35-44 10% 2% 17% 35-44 65+ 45-64 45-64 15% 17% 70% 62% Hormone Replacement Therapy Female Age Male Age $7bn ~80% of Patient Base ~20% of Patient Base (3) +7% CAGR Bioidentical pelle
Slide 14: Biote's End-to-End Practice-Building Platform
Biote’s End-to-End Practice-Building Platform Drives Clinic Success and Differentiates the Brand Biote Proprietary Business Model + + + + = Didactic and Proprietary Practice Clinical Access to High Practice Training Practice Retention Clinical Certification Management Decision Support Quality Dietar
Slide 15: Compelling Value Proposition for Providers
Compelling Value Proposition for Providers Number of Clinics ~2,800 2,606 2,166 1,616 1,112 2017A 2018A 2019A 2021A 2020A Annual Certified Clinic Financials Revenue per Average Procedure Ancillary Clinic Procedure Procedures Revenue Revenue Revenue + = Average Clinic $240 310 $74,400 $25,215 $99,615
Slide 16: Proven Model Poised for Significant Growth
Proven Model Poised for Significant Growth Opportunity to expand our universe of targeted providers Total providers in U.S. Including Physicians and NPs involved in Patient Care 1,200,000 Providers with relevant specialties Including IM, GP, FP, OB-GYN, Urology 260,000 Currently targeted specialty g
Slide 17: Geographic Scalability
Geographic Scalability Geographic scalability of the business is both predictable and capital efficient with a solid base of certified providers and their patients in current core states Today Future Near-Term Expansion Markets • Mid West (10 States) • Current core states include TX, OK, NM, CO, AR,
Slide 18: Impressive Financial Performance with Strong Growth, Profitability and Cash Flow
Impressive Financial Performance with Strong Growth, Profitability and Cash Flow Revenue EBITDA ($ in millions) ($ in millions) $160-166 $46-50 $139 $36 $116 $110 $33 $24 2019A 2020A 2021A 2022E 2019A 2020A 2021A 2022E % Gross Margin % Margin 60% 62% 65% 67% 22% 28% 26% ~29% ~20% ~20% ~29% 67% 2020A
Slide 19: Exceptional Leadership Team with a Proven Track Record
Exceptional Leadership Team with a Proven Track Record in Managing High Growth Businesses Terry Weber Marc Beer Robb Gibbins Chief Executive Officer Chairman Chief Financial Officer Joe Butler Cary Paulette Marybeth Conlon Kevin Key Jennifer Schimmel Chief Information Officer Vice President of Sales
Slide 20: Thank You
Thank You 20 Confidential Material – Do Not Distribute